MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

BACKGROUND: Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation of the AKT pathway promotes platinum resistance while inhibition of AKT sensitizes chemoresistant cells. Patients with BRCA mutant EOC, and thus a defect in the homologous recombinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Whicker, Margaret E., Lin, Z. Ping, Hanna, Ruth, Sartorelli, Alan C., Ratner, Elena S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964088/
https://www.ncbi.nlm.nih.gov/pubmed/27465688
http://dx.doi.org/10.1186/s12885-016-2598-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964088/
https://www.ncbi.nlm.nih.gov/pubmed/27465688
http://dx.doi.org/10.1186/s12885-016-2598-1

Ejemplares similares